Nutriband (NTRB) vs Verrica Pharmaceuticals (VRCA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Verrica Pharmaceuticals (VRCA) has outperformed Nutriband (NTRB) over the past year, losing 5.4% versus a loss of 28.8%. Over five years, NTRB leads with a -11.2% price change compared with -96.9% for VRCA. Nutriband is the larger company by market cap ($82.2 million vs $74.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTRB | VRCA |
|---|---|---|
| Share price | $6.76 | $4.35 |
| Market cap | $82.17M | $74.79M |
| 1-day change | +11.73% | +4.16% |
| YTD return | +33.26% | -49.70% |
| 1-year return | -28.82% | -5.43% |
| 5-year return | -11.15% | -96.87% |
| EPS (TTM) | $-0.53 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.19 | $9.82 |
| 52-week low | $2.80 | $3.28 |
| Distance from 52-week high | -26.40% | -55.67% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +121.90% | +217.65% |
| Average volume | 62.42K | 62.56K |
| Shares outstanding | 12.16M | 17.18M |
| Employees | — | 76 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRCA has outperformed NTRB by 23.4 percentage points over the past year.
About Nutriband
NTRB stock →Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States.
Health Care · Industrial Specialties
About Verrica Pharmaceuticals
VRCA stock →Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
NTRB vs VRCA FAQ
Which is bigger, Nutriband or Verrica Pharmaceuticals?
Nutriband (NTRB) is larger, with a market capitalization of $82.17M compared with $74.79M for Verrica Pharmaceuticals (VRCA).
Which stock has performed better over the past year, NTRB or VRCA?
VRCA returned -5.43% over the past 12 months, compared with -28.82% for NTRB (price return, excluding dividends). Past performance does not predict future results.
Are Nutriband and Verrica Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Nutriband and Biotechnology: Pharmaceutical Preparations for Verrica Pharmaceuticals.